Loading clinical trials...
Loading clinical trials...
A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination With Other Antiretroviral Agents in People Living With HIV
Conditions
Interventions
Oral Lenacapavir
F/TAF
+4 more
Locations
53
United States
Valleywise Community Health Center - McDowell
Phoenix, Arizona, United States
Pueblo Family Physicians
Phoenix, Arizona, United States
Ruane Clinical Research Group Inc
Los Angeles, California, United States
Mills Clinical Research at Men's Health Foundation
Los Angeles, California, United States
Eisenhower Health Center at Rimrock
Palm Springs, California, United States
University of Colorado, Denver, University of Colorado Hospital
Aurora, Colorado, United States
Start Date
November 22, 2019
Primary Completion Date
October 5, 2021
Completion Date
September 19, 2023
Last Updated
October 2, 2024
NCT07055451
NCT05136703
NCT05668026
NCT04174755
NCT06691321
NCT06631365
Lead Sponsor
Gilead Sciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions